817 related articles for article (PubMed ID: 34757380)
1. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
[TBL] [Abstract][Full Text] [Related]
2. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
[TBL] [Abstract][Full Text] [Related]
3. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
4. Waiting Period Before Implantable Cardioverter-Defibrillator Implantation in Newly Diagnosed Heart Failure With Reduced Ejection Fraction: A Window of Opportunity.
DeFilippis EM; Butler J; Vaduganathan M
Circ Heart Fail; 2017 Nov; 10(11):. PubMed ID: 29138249
[No Abstract] [Full Text] [Related]
5. Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization.
Bhagat AA; Greene SJ; Vaduganathan M; Fonarow GC; Butler J
JACC Heart Fail; 2019 Jan; 7(1):1-12. PubMed ID: 30414818
[TBL] [Abstract][Full Text] [Related]
6. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
[TBL] [Abstract][Full Text] [Related]
7. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effectiveness of Sacubitril/Valsartan Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction.
Greene SJ; Choi S; Lippmann SJ; Mentz RJ; Greiner MA; Hardy NC; Hammill BG; Luo N; Samsky MD; Heidenreich PA; Laskey WK; Yancy CW; Peterson PN; Curtis LH; Hernandez AF; Fonarow GC; O'Brien EC
J Am Heart Assoc; 2021 Aug; 10(16):e021459. PubMed ID: 34350772
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Patients with Heart Failure to Determine Eligibility for Treatment with Sacubitril/Valsartan: Insights from a Veterans Administration Healthcare System.
Han J; Chung F; Nguyen QL; Mody FV; Jackevicius CA
Pharmacotherapy; 2019 Nov; 39(11):1053-1059. PubMed ID: 31498903
[TBL] [Abstract][Full Text] [Related]
10. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
[TBL] [Abstract][Full Text] [Related]
11. Prevention of sudden death in heart failure with reduced ejection fraction: do we still need an implantable cardioverter-defibrillator for primary prevention?
Abdelhamid M; Rosano G; Metra M; Adamopoulos S; Böhm M; Chioncel O; Filippatos G; Jankowska EA; Lopatin Y; Lund L; Milicic D; Moura B; Ben Gal T; Ristic A; Rakisheva A; Savarese G; Mullens W; Piepoli M; Bayes-Genis A; Thum T; Anker SD; Seferovic P; Coats AJS
Eur J Heart Fail; 2022 Sep; 24(9):1460-1466. PubMed ID: 35753058
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a U.S. Academic Medical Center.
Bress AP; King JB; Brixner D; Kielhorn A; Patel HK; Maya J; Lee VC; Biskupiak J; Munger M
Pharmacotherapy; 2016 Feb; 36(2):174-86. PubMed ID: 26841333
[TBL] [Abstract][Full Text] [Related]
13. Inpatient Quality-of-Care Measures for Heart Failure: Treatment Gaps and Opportunities in the Contemporary Era.
Warner AL; Lu L; Ghaznavi Z; Jackevicius CA
Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008936. PubMed ID: 36252108
[TBL] [Abstract][Full Text] [Related]
14. Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.
Greene SJ; Butler J; Albert NM; DeVore AD; Sharma PP; Duffy CI; Hill CL; McCague K; Mi X; Patterson JH; Spertus JA; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Am Coll Cardiol; 2018 Jul; 72(4):351-366. PubMed ID: 30025570
[TBL] [Abstract][Full Text] [Related]
15. The evolution of guideline-directed medical therapy among decompensated HFrEF patients in sacubitril/valsartan era: Medical expenses and clinical effectiveness.
Liang HW; Liao CT; Lin WY; Chung FP; Huang JL; Lee YH; Lin PL; Chiou WR; Hsu CY; Chang HY
J Chin Med Assoc; 2021 Jun; 84(6):588-595. PubMed ID: 33901125
[TBL] [Abstract][Full Text] [Related]
16. Clinical Course of Patients With Worsening Heart Failure With Reduced Ejection Fraction.
Butler J; Yang M; Manzi MA; Hess GP; Patel MJ; Rhodes T; Givertz MM
J Am Coll Cardiol; 2019 Mar; 73(8):935-944. PubMed ID: 30819362
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hydralazine/Nitrate and Angiotensin Receptor Neprilysin Inhibitor Use Among Black Versus Nonblack Americans With Heart Failure and Reduced Ejection Fraction (from CHAMP-HF).
Giblin EM; Adams KF; Hill L; Fonarow GC; Williams FB; Sharma PP; Albert NM; Butler J; DeVore AD; Duffy CI; Hernandez AF; McCague K; Spertus JA; Thomas L; Patterson JH
Am J Cardiol; 2019 Dec; 124(12):1900-1906. PubMed ID: 31679641
[TBL] [Abstract][Full Text] [Related]
18. Background pharmacological therapy in the ANTHEM-HF: comparison to contemporary trials of novel heart failure therapies.
Premchand RK; Sharma K; Mittal S; Monteiro R; Libbus I; Ardell JL; Gregory DD; KenKnight BH; Amurthur B; DiCarlo LA; Anand IS
ESC Heart Fail; 2019 Oct; 6(5):1052-1056. PubMed ID: 31339232
[TBL] [Abstract][Full Text] [Related]
19. Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.
Vaduganathan M; Fonarow GC; Greene SJ; DeVore AD; Kavati A; Sikirica S; Albert NM; Duffy CI; Hill CL; Patterson JH; Spertus JA; Thomas LE; Williams FB; Hernandez AF; Butler J
JACC Heart Fail; 2020 Jun; 8(6):469-480. PubMed ID: 32387066
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
